Keywords: AstraZeneca, Brilinta, Brilique, Cost effectiveness, Nexium, Daiichi Sankyo, Japan

AstraZeneca’s blood thinner Brilinta/Brilique demonstrates cost effectiveness; new Nexium indication filed in Japan

Article | 24 October 2011

Print This

Data from eight countries shows that using Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) Brilique/Brilinta (ticagrelor) plus aspirin ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in